Compare Illumina, Inc. (ILMN) vs ProShares Ultra Gold ETF (UGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs ProShares Ultra Gold ETF — how do they compare? Illumina, Inc. trades at $268.9 (market cap $39.95B), while ProShares Ultra Gold ETF trades at $46.23 (market cap $716.59M). The key difference: Illumina, Inc. is far larger — about 55.8× ProShares Ultra Gold ETF's market cap, and Illumina, Inc. is trading nearer its 52-week high, ProShares Ultra Gold ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and ProShares Ultra Gold ETF for 23 Days on average.
| ILMN | UGL | |
|---|---|---|
Market Cap | $39.95B | $716.59M |
Volume | 3,169,503 | 2,592,878 |
Sector | Health | Leveraged / Inverse |
52-Week High | $293.69 | $85.62 |
52-Week Low | $91.00 | $42.79 |
Typical Hold Time | 83 Days | 23 Days |
Enterprise Value | $41.31B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $267.76, down 2.11% today but remains near recent highs after a strong 94.9% YTD rally. The stock shows bullish technical momentum with recent earnings beats and improved profitability, with net income turning positive to $850 million in 2025 after previous losses. S&P 500 inclusion in September 2026 and growing AI integration in genomics provide positive catalysts, though valuation metrics remain elevated with a P/E of 49.36.
Outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI adoption, while risks include China headwinds, margin pressure, and high valuation multiples requiring sustained execution to justify premium pricing.
UGL shares are trading at $44.43, down 3.29% with a bearish technical outlook as moving averages and oscillators signal selling pressure. The stock faces resistance at $45-$46 with support at $43-$44. Recent market sentiment reflects concerns about gold's performance amid rising Treasury yields and Federal Reserve policy uncertainty, creating headwinds for gold-related equities.
The stock's outlook remains challenged by macroeconomic pressures on gold prices, though potential Fed policy shifts could provide catalysts. Key risks include persistent high yields and dollar strength, while opportunities exist if inflation concerns reignite safe-haven demand. Investors should monitor Fed guidance and gold price trends for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About ProShares Ultra Gold ETF
UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.
Read more on UGL →
